Schizophrenia/Psychosis

Mental illnesses are too often shrouded in secrecy and shame. What would happen if we spoke out about the cases we knew best—the ones in our own families?

Secondary causes for psychosis are more common in older adults (65 years or older) than in younger patients. Here are 6 possible culprits.

The one-of-its-kind 6-month paliperidone palmitate treatment for schizophrenia has received FDA approval.

What can philosophy learn from madness?

The emergency department is a primary care location for patients with schizophrenia. Here’s how to manage schizophrenia in this particular setting in an informed and caring manner.

Most psychotic disorders appear in adolescents or young adults, but some also occur during later life. Here's how to recognize and treat them.

Artificial intelligence and natural language processing provide powerful new tools to measure thought disorder and negative symptoms in schizophrenia.

How is “disease” defined? A popular criticism of psychiatry gets debunked.

A growing body of scientific literature makes the case.

An extended release, ultra-long acting antipsychotic takes another step forward in the approval process.

New research may help better understand psychosis etiology as well as provide potential biomarkers for psychosis.

Cannabis has been heralded as a treatment for many conditions, but what about its psychiatric risks?

A recent study dives into the data.

Simple but powerful strategies for drawing on patients’ existing character strengths and long-term goals.

Being unable to experience pleasure and having difficulty imagining future enjoyment are different problems—and may require different treatments.

This combination treatment of olanzapine and samidorphan caused significantly less weight gain in patients with schizophrenia and bipolar I disorder.

Sleep problems are understudied, underdiagnosed, and undertreated.

There is debate whether schizoaffective disorder is a separate illness or is part of the continuum of schizophrenia and mood disorder spectrum.

This treatment for agitation associated with schizophrenia and bipolar disorder is moving up the FDA ladder…

Because schizophrenia is associated with increased inflammation, studies on the effects of anti-inflammatory statins are warranted.

Two posters presented at the APA virtual meeting demonstrated long-acting injectable positive results, costs savings, and increased telehealth for patients with schizophrenia.

Data presented at the 2021 APA Virtual Annual Meeting show promise for treating schizophrenia.

The sexual side effects of psychiatric medications are troubling enough that some patients consider treatment cessation. The authors review 5 strategies for managing sexual dysfunction.

There is evidence for overlapping risk factors and symptomatology between ADHD and psychotic disorders. New research investigates the association between ADHD during childhood and the subsequent risk of developing a psychotic disorder.

Ronald W Pies, MD, considers the evidence from pathology textbooks—and answers the critics.

A lawyer discusses how the legal system treats (and mistreats) those with mental illnesses.

A new risperidone capsule for the treatment of schizophrenia sees positive phase 2 study results.

Patient perspectives in academic discourse in psychiatry have historically been a neglected area. What are some of the consequences and implications of this absence? How has this affected both psychiatry and those who have been excluded? These questions and more are discussed.

A quick primer on nomenclature, issues to consider, and switching.